BridgeBio Pharma raises $250M in PIPE financing led by Qatar Investment Authority

BridgeBio Pharma, Inc.

Issues 9,167,723 shares at $27.27/share (Sept 22 close); gross proceeds ~$250M.
Financing led by QIA, with participation from four large US investment management firms.
Proceeds to fund acoramidis launch, Phase 3 readouts in achondroplasia, LGMD2I, ADH1, and general corporate purposes.
PIPE expected to close Sept 27, 2023, subject to customary conditions.
Company also exploring additional less dilutive financing options to optimize cost of capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BridgeBio Pharma, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $250 million (effective 2023-09-25).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $250 million
Effective: 2023-09-25

Exact text from the filing

On September 25, 2023, BridgeBio Pharma, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 9,167,723 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $27.27 per share.

View on SEC.gov

84 material agreements filed in the last 30 days. Browse all material agreements →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-049683

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.